Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant preoperative window study in ER+ breast cancer
NCT03916744Phase 1Completed
- Sponsor
- Genentech
- Start
- Jul 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of giredestrant in breast cancer (3 arms), sponsored by Genentech. Primary endpoints: Change From Baseline in Tumor Cell Proliferation (Proportion of Nuclei Staining Ki67-Positive) at Day 15 and Change From Baseline in Tumor Cell Proliferation (Difference in Percentage of Nuclei Staining Ki67-Positive) at Day 15. Started Jul 2019; status: completed.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03916744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916744.